Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2023-03-03 00:00:00 ET · period of report 2023-03-01 · accession 0001562180-23-002199 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-03-03 | 2023-03-01 | AKBA | Burke Steven Keith | SVP, Chief Medical Off | S - Sale | $0.88 | -14.1K | 601.6K | -2% | -$12.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-01 | S | D | 1,110 | $0.88 | 594,054 | D | — | — | (F3) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. |
| 2 | Common | Common Stock | 2023-03-01 | S | D | 6,400 | $0.88 | 595,164 | D | — | — | (F2) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. |
| 3 | Common | Common Stock | 2023-03-01 | S | D | 6,613 | $0.88 | 601,564 | D | — | — | (F1) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. |